← Leaderboards
Scott Budd Winram
Cynvec, Llc
$1,000,000
Attributed
$2,000,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2016–17$2M$1.5M$1M$500K$0
'16
'17
Funding mix
By agency
NIH$2,000,000 · 1
By mechanism
R44$2,000,000 · 1
Top collaborators
- Daniel Meruelo2 shared
Others in their field
Top investigators on “Affinity”
- Dennis R. Burton · Scripps Research Institute$64,397,776
- James E Crowe · Vanderbilt University Medical Center$53,471,415
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$45,445,140
- Timothy A Springer · Boston Children'S Hospital$41,593,445
- Misty Ward Stevens · Intervexion Therapeutics, Llc$38,187,594
- Rafi Ahmed · Emory University$36,776,987
Research focus
AffinityDisease RemissionAnimal EfficacyAnimalsApoptosisAdverse EffectsBaseBiotechnologyBloodCancer PatientCancer TherapyCause Of DeathAwardAlphavirusCellsChemotherapyClinical TrialsCombined Modality TherapyCommercializationContractorContractsConventional TherapyDepartment Of DefenseDisseminated Malignant Neoplasm
Grant awards (2)
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy$1,004,186
R44 · FY2017 · CA · contact PI
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy$995,814
R44 · FY2016 · CA · contact PI